Acetylsalicylic acid as an adjuvant therapy for schizophrenia

Wijnand Laan*, Jean-Paul Selten, Rene S. Kahn, Anne-Margriet Huisman, Cobi J. Heijnen, Diederick E. Grobbee, Huibert Burger

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

5 Citations (Scopus)
237 Downloads (Pure)

Abstract

Background: Findings from both epidemiological and basic research point to the possibility that NSAIDS impede the deterioration in schizophrenia.

Methods: To study the efficacy of acetylsalicylic acid we will perform a randomized placebo controlled double- blind add- on trial of 80 inpatients and outpatients with schizophrenia, schizophreniform or schizoaffective disorder. Patients will be 1: 1 randomized to either 3 months 1000 mg acetylsalicylic acid per day or 3 months placebo, in addition to their regular antipsychotic treatment. All patients will receive pantoprazole treatment for gastroprotection. The outcomes of this study are 3- month change in psychotic and negative symptom severity, cognitive function, and several immunological parameters.

This trial may ( 1) yield a new ( adjuvant) therapy for schizophrenia and ( 2) add to the knowledge on the pathogenesis of this major psychiatric disorder.

Original languageEnglish
Article number31
Pages (from-to)Art. No. 31-
Number of pages6
JournalTRIALS
Volume7
DOIs
Publication statusPublished - 23-Oct-2006

Keywords

  • NECROSIS-FACTOR-ALPHA
  • RHEUMATOID-ARTHRITIS
  • ANTIINFLAMMATORY DRUGS
  • ASPIRIN
  • IMMUNE
  • INTERLEUKIN-6
  • ASSOCIATION
  • HYPOTHESIS

Cite this